
Samantha L. Shterengarts
Examiner (ID: 2, Phone: (571)270-5316 , Office: P/1626 )
| Most Active Art Unit | 1626 |
| Art Unit(s) | 4131, 1623, 1626 |
| Total Applications | 2313 |
| Issued Applications | 1786 |
| Pending Applications | 96 |
| Abandoned Applications | 469 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18793848
[patent_doc_number] => 11827599
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-11-28
[patent_title] => Method of preparing ionic fluids
[patent_app_type] => utility
[patent_app_number] => 17/983873
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 5674
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 137
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17983873
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/983873 | Method of preparing ionic fluids | Nov 8, 2022 | Issued |
Array
(
[id] => 18597184
[patent_doc_number] => 20230271977
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/053459
[patent_app_country] => US
[patent_app_date] => 2022-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053459
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053459 | Exatecan derivatives, linker-payloads, and conjugates and thereof | Nov 7, 2022 | Issued |
Array
(
[id] => 18308012
[patent_doc_number] => 20230111912
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => SALTS OF A PIM KINASE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/981887
[patent_app_country] => US
[patent_app_date] => 2022-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31659
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17981887
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/981887 | Salts of a Pim kinase inhibitor | Nov 6, 2022 | Issued |
Array
(
[id] => 19247335
[patent_doc_number] => 20240198320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => ZIF-8 ORGANOMETALLIC FRAME CATALYST COMPOSITE, AND CARBON DIOXIDE CONVERSION METHOD USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/552589
[patent_app_country] => US
[patent_app_date] => 2022-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16027
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552589
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/552589 | ZIF-8 ORGANOMETALLIC FRAME CATALYST COMPOSITE, AND CARBON DIOXIDE CONVERSION METHOD USING SAME | Oct 30, 2022 | Pending |
Array
(
[id] => 19210646
[patent_doc_number] => 11999694
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Delivery of therapeutic alkaloid compounds
[patent_app_type] => utility
[patent_app_number] => 17/976150
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 14
[patent_no_of_words] => 57932
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17976150
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/976150 | Delivery of therapeutic alkaloid compounds | Oct 27, 2022 | Issued |
Array
(
[id] => 19012954
[patent_doc_number] => 11919869
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => CD73 compounds
[patent_app_type] => utility
[patent_app_number] => 18/050404
[patent_app_country] => US
[patent_app_date] => 2022-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 42172
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 193
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050404
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050404 | CD73 compounds | Oct 26, 2022 | Issued |
Array
(
[id] => 18363134
[patent_doc_number] => 20230144725
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => LRRK2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/049802
[patent_app_country] => US
[patent_app_date] => 2022-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52478
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049802
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/049802 | LRRK2 inhibitors | Oct 25, 2022 | Issued |
Array
(
[id] => 18326810
[patent_doc_number] => 20230124938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => GLP-1 RECEPTOR AGONISTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/049052
[patent_app_country] => US
[patent_app_date] => 2022-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 423
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049052
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/049052 | GLP-1 receptor agonists and uses thereof | Oct 23, 2022 | Issued |
Array
(
[id] => 18764000
[patent_doc_number] => 11814386
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/048079
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26980
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 687
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048079
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048079 | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors | Oct 19, 2022 | Issued |
Array
(
[id] => 18344628
[patent_doc_number] => 20230132738
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => HYDROPHILIC ANTIBODY-DRUG CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/963939
[patent_app_country] => US
[patent_app_date] => 2022-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26520
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17963939
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/963939 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | Oct 10, 2022 | Abandoned |
Array
(
[id] => 18837675
[patent_doc_number] => 11845736
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-19
[patent_title] => Prodrugs of MDMA, MDA, and derivatives thereof
[patent_app_type] => utility
[patent_app_number] => 17/959256
[patent_app_country] => US
[patent_app_date] => 2022-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24503
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17959256
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/959256 | Prodrugs of MDMA, MDA, and derivatives thereof | Oct 2, 2022 | Issued |
Array
(
[id] => 18365694
[patent_doc_number] => 20230147285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/936973
[patent_app_country] => US
[patent_app_date] => 2022-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22298
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936973
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/936973 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | Sep 29, 2022 | Issued |
Array
(
[id] => 20451792
[patent_doc_number] => 12514835
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => GABA complex composition
[patent_app_type] => utility
[patent_app_number] => 17/935949
[patent_app_country] => US
[patent_app_date] => 2022-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 0
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935949
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/935949 | GABA complex composition | Sep 27, 2022 | Issued |
Array
(
[id] => 18322057
[patent_doc_number] => 20230120185
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => HETEROCYCLIC AMIDES AS KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/935791
[patent_app_country] => US
[patent_app_date] => 2022-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47545
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935791
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/935791 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | Sep 26, 2022 | Abandoned |
Array
(
[id] => 18419997
[patent_doc_number] => 20230174457
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => INSECT REPELLENT COMPOUNDS AND COMPOSITIONS, AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/940585
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17013
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17940585
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/940585 | INSECT REPELLENT COMPOUNDS AND COMPOSITIONS, AND METHODS THEREOF | Sep 7, 2022 | Abandoned |
Array
(
[id] => 18524270
[patent_doc_number] => 20230234927
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/929931
[patent_app_country] => US
[patent_app_date] => 2022-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929931
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/929931 | PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS | Sep 5, 2022 | Abandoned |
Array
(
[id] => 18582815
[patent_doc_number] => 20230265070
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA
[patent_app_type] => utility
[patent_app_number] => 17/902512
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17902512
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/902512 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | Sep 1, 2022 | Pending |
Array
(
[id] => 19543055
[patent_doc_number] => 20240360091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH
[patent_app_type] => utility
[patent_app_number] => 18/688300
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24120
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18688300
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/688300 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | Sep 1, 2022 | Pending |
Array
(
[id] => 18420030
[patent_doc_number] => 20230174491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => DEUTERATED COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/929505
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35717
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929505
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/929505 | Deuterated compounds and uses thereof | Sep 1, 2022 | Issued |
Array
(
[id] => 19543055
[patent_doc_number] => 20240360091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH
[patent_app_type] => utility
[patent_app_number] => 18/688300
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24120
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18688300
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/688300 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | Sep 1, 2022 | Pending |